62 related articles for article (PubMed ID: 8977296)
1. The CD8 beta polypeptide is required for the recognition of an altered peptide ligand as an agonist.
Renard V; Delon J; Luescher IF; Malissen B; Vivier E; Trautmann A
Eur J Immunol; 1996 Dec; 26(12):2999-3007. PubMed ID: 8977296
[TBL] [Abstract][Full Text] [Related]
2. Modulation of naive CD4 T cell activation with altered peptide ligands: the nature of the peptide and presentation in the context of costimulation are critical for a sustained response.
Rogers PR; Grey HM; Croft M
J Immunol; 1998 Apr; 160(8):3698-704. PubMed ID: 9558070
[TBL] [Abstract][Full Text] [Related]
3. Antigen presentation by T cells inhibits IL-2 production and induces IL-4 release due to altered cognate signals.
Lombardi G; Hargreaves R; Sidhu S; Imami N; Lightstone L; Fuller-Espie S; Ritter M; Robinson P; Tarnok A; Lechler R
J Immunol; 1996 Apr; 156(8):2769-75. PubMed ID: 8609395
[TBL] [Abstract][Full Text] [Related]
4. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone.
Zügel U; Schoel B; Kaufmann SH
J Immunol; 1994 Nov; 153(9):4070-80. PubMed ID: 7523514
[TBL] [Abstract][Full Text] [Related]
5. Loss of CD8 and TCR binding to Class I MHC ligands following T cell activation.
Kao C; Daniels MA; Jameson SC
Int Immunol; 2005 Dec; 17(12):1607-17. PubMed ID: 16263755
[TBL] [Abstract][Full Text] [Related]
6. Four types of Ca2+ signals in naive CD8+ cytotoxic T cells after stimulation with T cell agonists, partial agonists and antagonists.
Bachmann MF; Mariathasan S; Bouchard D; Speiser DE; Ohashi PS
Eur J Immunol; 1997 Dec; 27(12):3414-9. PubMed ID: 9464830
[TBL] [Abstract][Full Text] [Related]
7. Comparison of phosphorylation and internalization of the antigen receptor/CD3 complex, CD8, and class I MHC-encoded proteins on T cells. Role of intracytoplasmic domains analyzed with hybrid CD8/class I molecules.
Boyer C; Auphan N; Gabert J; Blanc D; Malissen B; Schmitt-Verhulst AM
J Immunol; 1989 Sep; 143(6):1905-14. PubMed ID: 2506271
[TBL] [Abstract][Full Text] [Related]
8. Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation.
Abe R; Vandenberghe P; Craighead N; Smoot DS; Lee KP; June CH
J Immunol; 1995 Feb; 154(3):985-97. PubMed ID: 7822814
[TBL] [Abstract][Full Text] [Related]
9. Patterns of costimulation of T cell clones by cross-linking CD3, CD4/CD8, and class I MHC molecules.
Wacholtz MC; Patel SS; Lipsky PE
J Immunol; 1989 Jun; 142(12):4201-12. PubMed ID: 2470819
[TBL] [Abstract][Full Text] [Related]
10. Heterologous cross-linking of Lyt-2 (CD8) to the alpha beta-T cell receptor is more effective in T cell activation than homologous alpha beta-T cell receptor cross-linking.
Boyce NW; Jönsson JI; Emmrich F; Eichmann K
J Immunol; 1988 Nov; 141(9):2882-8. PubMed ID: 3262671
[TBL] [Abstract][Full Text] [Related]
11. Specific epitope-induced conversion of CD8+ memory cells into effector cytotoxic T lymphocytes in vitro: presentation of peptide antigen by CD8+ T cells.
Kos FJ; Müllbacher A
Eur J Immunol; 1992 Jun; 22(6):1595-601. PubMed ID: 1376266
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of CD28 engagement and IL-12 on T cell activation by altered peptide ligands.
Ding L; Shevach EM
J Immunol; 1998 Dec; 161(12):6614-21. PubMed ID: 9862689
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of cytotoxic T-lymphocyte activation by soluble CD8.
Sewell AK; Gerth UC; Price DA; Purbhoo MA; Boulter JM; Gao GF; Bell JI; Phillips RE; Jakobsen BK
Nat Med; 1999 Apr; 5(4):399-404. PubMed ID: 10202928
[TBL] [Abstract][Full Text] [Related]
14. Differential requirements for CD4 in TCR-ligand interactions.
Vidal K; Daniel C; Hill M; Littman DR; Allen PM
J Immunol; 1999 Nov; 163(9):4811-8. PubMed ID: 10528181
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
16. Cognate peptide-induced destruction of CD8+ cytotoxic T lymphocytes is due to fratricide.
Su MW; Walden PR; Golan DB; Eisen HN
J Immunol; 1993 Jul; 151(2):658-67. PubMed ID: 8335901
[TBL] [Abstract][Full Text] [Related]
17. Is the activity of partially agonistic MHC:peptide ligands dependent on the quality of immunological help?
Uhlin M; Masucci M; Levitsky V
Scand J Immunol; 2006 Dec; 64(6):581-7. PubMed ID: 17083613
[TBL] [Abstract][Full Text] [Related]
18. Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity.
Krogsgaard M; Li QJ; Sumen C; Huppa JB; Huse M; Davis MM
Nature; 2005 Mar; 434(7030):238-43. PubMed ID: 15724150
[TBL] [Abstract][Full Text] [Related]
19. Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands.
Dressel A; Chin JL; Sette A; Gausling R; Höllsberg P; Hafler DA
J Immunol; 1997 Nov; 159(10):4943-51. PubMed ID: 9366420
[TBL] [Abstract][Full Text] [Related]
20. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
Lustgarten J; Waks T; Eshhar Z
Eur J Immunol; 1991 Oct; 21(10):2507-15. PubMed ID: 1915555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
